This bill requires health insurance plans in New Jersey to continue covering adult children with disabilities who are 26 or older, provided they cannot work due to a physical or intellectual disability and are financially dependent on their parent. It amends existing law to extend coverage beyond the standard age limit of 26 for this specific group, ensuring they maintain health insurance through their parent's plan. The bill prohibits denial of coverage based on factors like marriage, having a child, or school status, which commonly affected young adults with disabilities. This change directly impacts young adults with disabilities in New Jersey who would otherwise lose coverage at age 26 but meet the eligibility criteria.
This bill requires social media platforms with significant user activity in New Jersey to display prominent warning labels about mental health risks during account sign-up and when users access certain features. It specifically targets platforms that allow social interaction (like profile creation and content sharing) and directly affects minors under 18, as defined by the bill. The warnings must highlight risks identified by the U.S. Surgeon General, including links between heavy social media use and increased depression, anxiety, and sleep disruption in youth. Platforms must comply with these labeling requirements to inform users and families about potential harms. The bill does not impose additional restrictions beyond the warning labels.
This bill requires health insurance carriers in New Jersey to allow clinical laboratories and laboratory services providers to join their provider networks as preferred or contracting partners. The legislation mandates that insurance contracts must not deny these providers the right to participate under the same terms and conditions applied to other providers, provided they hold the necessary state or federal licenses and agree to the contract's terms. Additionally, the bill ensures that subscribers can choose their own laboratories without facing higher copayments or fees compared to other options, while also prohibiting insurers from restricting how providers charge for additional services like prescription counseling. These changes aim to increase competition and choice for patients by ensuring laboratories have equal access to insurance networks.
This bill prohibits health insurance carriers from denying coverage for nonopioid pain medications in favor of opioids or requiring patients to try opioids first. It requires insurers to treat FDA-approved nonopioid drugs equally to opioids in formularies, meaning coverage restrictions, prior authorization, and cost-sharing tiers must be no more restrictive for nonopioid drugs. The law applies to state health benefit plans, school employee health programs, and Medicaid for acute pain treatment. It takes effect January 1, 2026, directly affecting insurers and patients covered by these plans.
This bill would require New Jersey Medicaid to cover ovulation-enhancing drugs and related medical services without restrictions for beneficiaries experiencing infertility. It directly affects low-income New Jersey residents enrolled in Medicaid who seek infertility treatment. The key provision amends Medicaid law to explicitly include these services as a standard benefit, removing prior authorization requirements. This change would expand current coverage to ensure these treatments are accessible as routine care for eligible individuals.
This bill authorizes certified medication aides to administer medications to residents in New Jersey nursing homes, expanding their current scope of practice. It directly affects nursing homes struggling with staffing shortages and certified medication aides who would now be permitted to perform this role in nursing home settings (currently allowed in 38 states and other care facilities like assisted living residences). The key mechanism is amending existing law to explicitly include nursing homes under the certification framework for medication aides, addressing legislative findings that staffing challenges are severe in nursing homes post-pandemic. This change aims to alleviate staffing pressures by allowing medication aides to support resident care needs within existing certification standards.
This bill expands New Jersey's existing requirement for health insurance plans to cover prostate cancer screenings without any out-of-pocket costs. It specifically requires coverage for annual screenings - including digital rectal exams and PSA tests - for men aged 50 and older (asymptomatic) and men aged 40 and older with a family history of prostate cancer or other risk factors. The law applies to most health insurance plans, including high-deductible plans where permitted by federal law, and mandates coverage "to the same extent as for any other medical condition." It does not alter existing coverage for other preventive services but ensures no cost-sharing (like deductibles or copays) applies to these specific screenings.
This bill exempts drug manufacturers and distributors from New Jersey's pharmacy licensing requirements when distributing dialysate drugs and devices used for home dialysis treatment of end-stage renal disease patients. It directly affects dialysis manufacturers, distributors, and patients receiving home dialysis, allowing them to bypass standard pharmacy licensing rules under six specific conditions. Key provisions include requiring FDA approval, direct delivery only upon physician orders, original sealed packaging, and mandatory weekly quality checks by a consultant pharmacist. The law ensures these products are handled safely while streamlining access for patients needing home dialysis.
This New Jersey bill creates a new crime called fertility fraud, which specifically targets licensed health care practitioners who knowingly use a patient's reproductive material without their written consent. Under the law, a practitioner commits this offense if they use their own sperm or eggs or the material of another person to cause a pregnancy without the patient's informed agreement. If convicted of this third-degree crime, the individual faces up to five years in prison, a fine of $15,000, and the mandatory permanent revocation of their medical license. Additionally, the legislation extends the statute of limitations for prosecuting this specific offense to 20 years from the date of the treatment or 10 years from when the victim discovers the fraud, whichever is later.
This bill requires state agencies to assess substance and alcohol use disorder treatment providers for conflicts of interest before approving state funding, licensure, or certification. Providers must submit detailed financial information, board member details, and lists of stakeholders with financial ties. If a conflict is identified that could affect care quality, the provider has 90 days to resolve it or risk losing funding/approval. After resolution, providers must undergo two additional conflict assessments within the next year. The law applies to all licensed or certifying state entities and defines conflicts as situations where outside financial interests might influence treatment decisions.
